Pharmaceuticals, Biotechnology and Life Sciences
Transformative Initiative Expected to Accelerate Development of CH5126766 (VS-6766), a RAF/MEK Inhibitor, in Combination with Defactinib, a FAK Inhibitor, for…
DUBLIN–(BUSINESS WIRE)–The “Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering.…
Provides Newborn Screening Technology for Two-Year SCID Evaluation Program WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for…
TORRANCE, Calif.–(BUSINESS WIRE)–#3Dbrain–Celprogen Inc., a global leader in the Stem Cell Research and Therapeutics industry for stem cell research since…
LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502…
— Company Achieves Multiple Clinical and Corporate Development Milestones in 2019, Advancing Core Pipeline Candidates; Expanding and Progressing Existing Collaborative…
2020 data milestones remain on track for proprietary programs SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a…
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on…